TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01249144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular Lens (IOL)
Description: Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular Lens (IOL)
Description: Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
Study: NCT02026583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study: NCT01720407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod cream + surgery
Description: Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + surgery
Description: Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
Study: NCT01794351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol
Description: In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
Study: NCT01794351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol
Description: In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
Study: NCT02978040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
Study: NCT01217645

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 150 mg [14C] AZD6765
Study: NCT03430362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine N Butylbromide
Description: 7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: Group B, will receive 2 ml of normal saline single intravenous dose
Study: NCT01150305

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Peripheral whole blood sample, 5 ml

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Peripheral whole blood sample, 5 ml
Study: NCT04430140

Intervention type: DEVICE
Intervention: CT Scan
Description: CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6
Study: NCT02836795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study: NCT02675660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Homoarginine
Description: 125 mg L-homoarginine once daily
Study: NCT01490047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
Study: NCT03507205

Intervention type: DEVICE
Intervention: Xience Prime
Description: Durable polymer-coated everolimus-eluting stents

Intervention type: DEVICE
Intervention: Xience V/Promus; Cypher
Description: Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents

Intervention type: DEVICE
Intervention: DP-ZES-RI
Description: Durable polymer-coated zotarolimus-eluting stents
Study: NCT02675660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules once daily
Study: NCT03023358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 30mg po twice a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750mg/m2 iv on day 1
Study: NCT01254643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
Study: NCT03023072

Intervention type: OTHER
Intervention: Incontinence Detection System
Study: NCT03507205

Intervention type: DEVICE
Intervention: Endeavor; Resolute
Description: Durable polymer-coated zotarolimus-eluting stents
Study: NCT01576497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA with suction
Description: For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA without suction
Description: For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
Study: NCT04339829

Intervention type: DRUG
Group type: OTHER
Intervention: Dacomitinib
Description: Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
Study: NCT00721240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: 5mg montelukast once daily for 12 weeks
Study: NCT03023358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750mg/m2 iv on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal doxorubicin
Description: 30mg/m2 iv on day 1
Study: NCT01991236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
Study: NCT03023358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 30mg/m2 iv on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4mg/m2 iv on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4mg/m2 iv on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100mg/d po on day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100mg/d po on day 1-5
Study: NCT01411761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reflor
Description: 5 million unit/day, first 15 day of life

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: serum physiologic
Description: 1 cc added to one feeding in a day
Study: NCT00516698

Intervention type: GENETIC
Intervention: polymorphism analysis
Study: NCT01991236

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Script
Description: Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
Study: NCT04515758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Cognitive Training
Description: Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training Only
Description: Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
Study: NCT00516698

Intervention type: OTHER
Intervention: high performance liquid chromatography
Study: NCT04649515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Placebo
Study: NCT01219985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard and respiratory-gated PET acquisitions
Description: After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~* Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~* Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations.
Study: NCT03186729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombotic Agent
Description: Anticoagulant or antiplatelet drugs
Study: NCT00516698

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Intervention: radiomammography
Study: NCT03661281

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Jebsen Taylor Hand function test
Description: consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
Study: NCT04488926

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules
Description: Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo microgranules 1800mg
Description: Placebo was prepared to be indistinguishable from color and flavor from the Product
Study: NCT03661281

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pinch strength
Description: Measured in every splint position using a standard dynamometer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Grooved pegboard test
Description: Time will be measured and compared between control, MP splint and IP splint
Study: NCT04488926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: (antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Therapy
Description: (antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Drug
Description: Use as needed allowed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Drug
Description: Use as needed allowed
Study: NCT04406649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study: NCT05528393

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: blood sampling
Study: NCT04254848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral stereognostic test
Description: Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
Study: NCT01807598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Study: NCT04514822

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic PET
Description: After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic PET
Description: After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
Study: NCT03977103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose irradiation conditioning + Treg/Tcon
Description: High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
Study: NCT01849406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal spray Budesonide
Description: one week therapy of nasal budesonide twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray Normal Saline
Description: one week therapy of nasal normal saline twice per day
Study: NCT02717494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV-23
Description: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV-23
Description: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-10
Description: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-10
Description: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-10
Description: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
Study: NCT01887184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1.5mcg/kg was given intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal saline was given
Study: NCT03960112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
Study: NCT01940835

Intervention type: PROCEDURE
Intervention: Upper endoscopy with small bowel biopsies and brushings.

Intervention type: PROCEDURE
Intervention: Upper endoscopy with small bowel biopsies and brushings.

Intervention type: OTHER
Intervention: Blood draw
Description: Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).

Intervention type: OTHER
Intervention: Blood draw
Description: Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).

Intervention type: OTHER
Intervention: Stool sample
Description: Stool samples will be collected at baseline for future microbiome and virome studies.

Intervention type: OTHER
Intervention: Stool sample
Description: Stool samples will be collected at baseline for future microbiome and virome studies.
Study: NCT00292019

Intervention type: PROCEDURE
Intervention: Laparoscopic
Description: Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
Study: NCT00731679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01374633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Sevoflurane
Description: Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics.
Study: NCT04479774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compelled Body Weight Shift Technique
Description: Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10.

Intervention type: OTHER
Group type: OTHER
Intervention: Compelled Body Weight Shift Technique without insole
Description: Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10.
Study: NCT01633164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI Reinvention Protocol Participants
Description: The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Group
Description: Wait list arm will begin study intervention after 4 1/2 months.